# Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

> **NCT03109730** · PHASE1,PHASE2 · COMPLETED · sponsor: **Assembly Biosciences** · enrollment: 38 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABI-H0731
- **DRUG:** Placebo for ABI-H0731
- **DRUG:** Entecavir
- **DRUG:** Tenofovir Disoproxil Fumarate
- **DRUG:** Pegasys

## Key facts

- **NCT ID:** NCT03109730
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-15
- **Primary completion:** 2018-03-31
- **Final completion:** 2018-06-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2018-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03109730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03109730, "Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03109730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*